Evidence map›Paper›PMID 33791246›Full record

ArticleFrontiers in cellular and infection microbiology2021

Assessing

Kristien Cloots, Om Prakash Singh, Abhishek Kumar Singh, Gert Van der Auwera, Prashant Kumar, Mallikarjuna Rao Gedda, Tulika Kumari Rai, Epco Hasker, Shyam Sundar, Marleen Boelaert

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Precision Medicine in Control of Visceral Leishmaniasis Caused byFrontiers in cellular and infection microbiology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Kristien ClootsDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Om Prakash SinghDepartment of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India.
Abhishek Kumar SinghInfectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Gert Van der AuweraDepartment of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Prashant KumarKala-azar Medical Research Centre, Muzaffarpur, India.
Mallikarjuna Rao GeddaInfectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Tulika Kumari RaiInfectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Epco HaskerDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Shyam SundarInfectious Diseases Research Laboratory, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
Marleen BoelaertDepartment of Public Health, Institute of Tropical Medicine, Antwerp, Belgium.
Instituut voor Tropische Geneeskunde · BEInstitute of Medical Sciences · INBanaras Hindu University · INKala-Azar Medical Research Centre

Funding

Visceral Leishmaniasis in Bihar State, IndiaU19AI074321 · NIAID · BANARAS HINDU UNIVERSITY · PI SUNDAR, SHYAM · 2017 to 2021
$2.8M
NIAID NIH HHS U19 AI074321
6 · The paper itself

Abstract

Background: In the endgame of the elimination initiative of visceral leishmaniasis (VL) on the Indian subcontinent, one of the main questions remaining is whether asymptomatically infected individuals also contribute to transmission. We piloted a minimally invasive microbiopsy device that could help answer this question. While the potential of this device has been previously illustrated in Ethiopia, no such information is available for the setting of the Indian subcontinent. In this proof of concept study we aimed to assess 1) to what extent skin parasite load obtained with the new microbiopsy device correlates with disease status, 2) to what extent skin parasite load correlates with blood parasite load in the same subject, and 3) to what extent the skin parasite load obtained from different sampling sites on the body correlates with one another. Methods: We performed a pilot study in Bihar, India, including 29 VL patients, 28 PKDL patients, 94 asymptomatically infected individuals, 22 endemic controls (EC), and 28 non-endemic controls (NEC). Presence of infection with Findings: We found a clear correlation between the skin parasite load obtained with the microbiopsy device and disease status, with both higher skin parasite loads and higher proportions of positive skin samples in VL and PKDL patients compared to asymptomatics, EC, and NEC. No clear correlation between skin parasite load and blood parasite load was found, but a moderate correlation was present between the skin parasite load in arm and neck samples. In addition, we found four positive skin samples among asymptomatic individuals, and 85% of PKDL lesions tested positive using this microbiopsy device. Conclusions: In line with previous pilot studies, our results from an Indian setting suggest that the microbiopsy device provides a promising tool to measure skin parasite load, and - if validated by xenodiagnosis studies - could facilitate much needed larger scale studies on infectiousness of human subgroups. In addition, we advocate further evaluation of this device as a diagnostic tool for PKDL.

Indexed as

Leishmania donovaniLeishmaniasis, CutaneousEthiopiaHumansIndiaParasite LoadPilot ProjectsProof of Concept StudyIndiainfectiousnessinnovative toolsLeishmaniasisproof of concept studyskin parasites

Identifiers

PMID33791246
PMCPMC8006290
OpenAlexW3133709028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.